B-cell receptor pathway modulators in NHL.

about

Gene mutations and actionable genetic lesions in mantle cell lymphoma.A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.

P2860

Q37629080-016D1C0D-0878-4668-911C-46CB317B99D0 Q54112410-9FD924B2-063D-437F-86F8-1D8E86EF1DEE

P2860

B-cell receptor pathway modulators in NHL.

Item

http://www.wikidata.org/entity/Q38659428

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

B-cell receptor pathway modulators in NHL.

@en

type

Item

label

B-cell receptor pathway modulators in NHL.

@en

prefLabel

B-cell receptor pathway modulators in NHL.

@en

P1476

B-cell receptor pathway modulators in NHL.

@en

P2093

Kristie A Blum

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.

P304

82-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/ASHEDUCATION-2015.1.82

http://www.w3.org/2001/XMLSchema#string

P478

2015

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26637705

http://www.w3.org/2001/XMLSchema#string

P932

4871119

http://www.w3.org/2001/XMLSchema#string

B-cell receptor pathway modulators in NHL.

about

P2860

P2860

B-cell receptor pathway modulators in NHL.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932